The Ebola virus glycoprotein (GP) is the only viral protein exposed on the surface of the virion and is essential for viral attachment, receptor binding, membrane fusion, and host cell entry. GP is synthesized as a precursor that is cleaved into the GP1 and GP2 subunits, which assemble into trimeric spikes on the viral envelope. Because GP is the primary target of neutralizing antibodies and protective immune responses, it has become a major antigen for Ebola virus diagnostics, vaccine development, and therapeutic antibody research.

The Mayinga 1976 strain was isolated during the first recorded Ebola virus outbreak in Zaire (now the Democratic Republic of the Congo) and remains one of the best-characterized reference strains for Ebola virus research. eEnzyme's Anti-GP (Zaire Ebola Virus Mayinga 1976) Rabbit Polyclonal Antibody is generated against recombinant Mayinga GP and recognizes multiple epitopes across the viral glycoprotein. The antibody is suitable for applications including ELISA, Western blotting, immunofluorescence, immunohistochemistry, antigen characterization, vaccine evaluation, and basic filovirus research.

Selected Citation:
1) Characterization of rVSVΔG-ZEBOV-GP glycoproteins using automated capillary western blotting. Vaccine 38, 7166–7174 (2020). 
2) Serology and behavioral perspectives on Ebola virus disease among bushmeat vendors in equateur, democratic republic of the Congo, after the 2018 outbreak. in Open forum infectious diseases 7, ofaa295 (Oxford University Press US, 2020).